Mp11-10 Utility of Multiparametric Magnetic Resonance Imaging (Mpmri) in the Evaluation of Men for Active Surveillance of Prostate Cancer

Salami, Simpa S.; Sonstegard, Anna Marie; Yaskiv, Oksana; Türkbey, Barış; Villani, Robert; Ben-Levi, Eran; Rastinehad, Ardeshir R.

doi:10.1016/j.juro.2015.02.391

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who are eligible for active surveillance (AS) on their initial diagnostic biopsy often receive an MRI as well as a confirmatory biopsy [15, 16]. The suspicion level on MRI correlates with likelihood of detection of high-grade prostate cancer [10, 17–19]. TRUS saturation biopsy has also been used to monitor patients on AS, but can have significant morbidity [20].…”

Section: Introductionmentioning

confidence: 99%

Molecular imaging and fusion targeted biopsy of the prostate

Fei

Nieh

Master

et al. 2016

Clin Transl Imaging

View full text Add to dashboard Cite

Purpose This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

show abstract